Chen Shengdi, Chan Piu, Sun Shenggang, Chen Haibo, Zhang Baorong, Le Weidong, Liu Chunfeng, Peng Guoguang, Tang Beisha, Wang Lijuan, Cheng Yan, Shao Ming, Liu Zhenguo, Wang Zhenfu, Chen Xiaochun, Wang Mingwei, Wan Xinhua, Shang Huifang, Liu Yiming, Xu Pingyi, Wang Jian, Feng Tao, Chen Xianwen, Hu Xingyue, Xie Anmu, Xiao Qin
Department of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 China.
Xuanwu Hospital affiliated to Capital Medical University, Beijing, China.
Transl Neurodegener. 2016 Jun 30;5:12. doi: 10.1186/s40035-016-0059-z. eCollection 2016.
Parkinson's disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson's Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved.
To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD.
A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
帕金森病（PD）是一种慢性、进行性且使人衰弱的疾病，在中国影响着超过250万人。PD的临床特征为静止性震颤、肌肉僵硬、运动迟缓及姿势不稳。随着疾病进展，可能会出现其他并发症，如非运动和神经行为症状。中国已实施针对PD的药物治疗和手术干预。直到10年前，中国不同地区和不同医生对PD的管理缺乏标准化，导致不同地区和不同医生的治疗水平存在差异。从那时起，中华医学会神经病学分会帕金森病及运动障碍学组分别于2006年、2009年和2014年发布了三个版本的中国帕金森病治疗指南。相应地，中国PD的整体治疗水平有所提高。
根据当前国内外实践指南和临床证据更新治疗指南，改善医生在PD管理中的治疗选择。
治疗指南中提出了多种治疗建议，包括体育活动和疾病修饰药物，应在疾病早期开始使用。应遵循剂量滴定原则，以避免药物的急性不良反应，低剂量达到满意的临床效果并降低长期运动并发症的发生率。此外，在疾病的不同阶段应考虑不同的治疗策略。重要的是，治疗指南和个性化治疗应同等重视。已制定了一套治疗建议，以帮助中国医生改善和优化PD患者的临床结局。
